Safety and Efficacy of Rivaroxaban versus Low Molecular Weight Heparins for the Prevention of Venous Thromboembolism in Patients Undergoing Total Hip or Knee Arthroplasty in Routine Practice

Trial Profile

Safety and Efficacy of Rivaroxaban versus Low Molecular Weight Heparins for the Prevention of Venous Thromboembolism in Patients Undergoing Total Hip or Knee Arthroplasty in Routine Practice

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Jun 2014

At a glance

  • Drugs Rivaroxaban (Primary) ; Low molecular weight heparins
  • Indications Venous thromboembolism
  • Focus Adverse reactions
  • Most Recent Events

    • 19 Jun 2014 Trial phase assumed based on patients number.
    • 18 Jun 2014 New trial record
    • 10 Dec 2013 This study met its primary end points (Emergency-department-admission-because-of-treatment-failure and Hospitalisation).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top